Clinical Trial Update: Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib for relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED